(NASDAQ: XLO) Xilio Therapeutics's forecast annual revenue growth rate of 26.7% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Xilio Therapeutics's revenue in 2025 is $15,001,000.On average, 1 Wall Street analysts forecast XLO's revenue for 2025 to be $2,365,944,092, with the lowest XLO revenue forecast at $2,365,944,092, and the highest XLO revenue forecast at $2,365,944,092. On average, 1 Wall Street analysts forecast XLO's revenue for 2026 to be $4,236,931,643, with the lowest XLO revenue forecast at $4,236,931,643, and the highest XLO revenue forecast at $4,236,931,643.
In 2027, XLO is forecast to generate $675,835,946 in revenue, with the lowest revenue forecast at $675,835,946 and the highest revenue forecast at $675,835,946.